Healthcare technology is entering a new phase in which the boundary between personal health monitoring and professional medical care is becoming increasingly blurred. A major development announced in November 2026 illustrates this shift: wearable technology company Oura has agreed to acquire AI-powered primary care startup Counsel Health in a deal valued at approximately $625 million.
The proposed acquisition represents a significant strategic move for Oura, widely recognised for its smart rings that monitor sleep, activity and other biometric indicators. Instead of limiting its role to collecting health-related data, the company is moving towards a model that connects personal monitoring with medical guidance and access to healthcare professionals.
Counsel Health operates an AI-powered healthcare platform designed to provide medical information and connect users with physicians. Through the proposed integration, Oura aims to combine information collected by its wearable devices with AI-supported healthcare services. The companies are targeting preventive care, short-term health concerns and longer-term specialty and chronic care.
The transaction is expected to close before the end of 2026, subject to the necessary conditions. It is an announced acquisition agreement, not a completed transaction.
Another important development came from the US Food and Drug Administration on November 13. The agency approved Roche’s Gazyva, also known as obinutuzumab, as the first specifically approved treatment for adults with primary membranous nephropathy who are at risk of disease progression.
The approval is significant because primary membranous nephropathy is a rare kidney disease that can lead to serious complications, including kidney failure. Clinical trial results supporting the approval reported complete remission at 104 weeks in 36% of patients receiving Gazyva, compared with 6% receiving tacrolimus.
Together, these developments demonstrate two different dimensions of healthcare innovation. One is focused on connecting technology, data and medical professionals. The other is advancing treatment options for patients with conditions that have historically had limited specifically approved therapies.

However, digital healthcare expansion also creates important responsibilities. Biometric information from wearable devices cannot independently establish a medical diagnosis. AI-generated guidance must be supported by appropriate clinical oversight, privacy protection and clear safeguards against inaccurate recommendations.
For hospitals, insurers, pharmaceutical companies and technology developers, the opportunity lies in creating connected systems that make healthcare more accessible without compromising medical standards.
The next stage of healthcare may not be defined by a single device or breakthrough medicine. It could emerge from the integration of continuous monitoring, responsible artificial intelligence, clinical research and professional medical care.
As these developments progress, the most valuable healthcare innovations will be those that translate technology into meaningful improvements in patient access, safety and outcomes.




